Loading...
228760
XKRX
Market cap148mUSD
Nov 20, Last price  
8,060.00KRW
1D
-8.10%
1Q
-33.28%
Jan 2017
79.11%
IPO
78.78%
Name

Genomictree Inc

Chart & performance

D1W1MN
XKRX:228760 chart
P/E
—
P/S
53.30
EPS
—
Vol. 1Y
68.32%
Shs. 5Y
3.73%
Rev. 5Y
24.86%
Div Yld LY
—
Div Yld TTM
—
Revenues
3.76b
+59.17%
1,048,552,690548,337,980453,558,900386,945,800281,625,8701,238,850,8005,139,615,07029,865,674,7003,418,009,3702,362,308,0003,760,070,000
Net income
-8.99b
L-12.27%
-1,228,377,580-2,060,879,750-2,112,984,730-2,484,448,580-10,380,382,320-11,723,293,960-11,424,524,210-6,237,388,500-8,756,036,780-10,242,377,000-8,985,720,000
CFO
-7.24b
L-46.87%
-697,294,830-669,235,380-1,835,719,600-2,080,322,400-8,766,831,130-10,187,576,640-7,630,666,3204,285,629,190-10,880,529,590-13,633,430,000-7,243,747,873

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genomictree Inc is a molecular diagnostics firm focused on innovating technologies that address critical, unmet demands within the healthcare industry.

Key people

Hong Seon Lee
Chief Financial Officer, Assistant Managing Director · since 2020
Chi Wang Yoon
Vice President, Director · since 2000
Yong Wun Lee
Assistant Managing Director · since 2018
Jik Yeol Yoo
Internal Auditor · since 2020
Seong Hwan Ahn
Chief Executive Officer, Director · since 2000
Tae Jeong Oh
Managing Director · since 2001
Dong Jun Jung
Non-Executive Independent Director
IPO date
Jul 19, 2016
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT